Skip to main content
Products / Phyto
gBETA Pitch

3IT Phyto

Computational Ethnopharmacology Platform

Evidence-based platform connecting traditional medicine knowledge with modern scientific validation. Screens 908K+ compounds across 14K+ medicinal plants to identify bioactive ingredients with defensible efficacy claims.

14,678
Medicinal Plants
908,488
Compounds with Structures
2.5M+
Bioactivity Records
833K+
Traditional Uses Mapped

R&D Engine

Powered by 3IT Data Lake

The Phyto platform is the computational screening engine that powers all three market tracks below. One platform, three markets — each leveraging the same proprietary compound intelligence.

+ Multi-target network pharmacology and drug-likeness scoring
+ ADMET prediction and bioavailability profiling
+ Cross-tradition convergence analysis (Ayurveda, TCM, Unani)
+ Compound-to-claim evidence dossier generation
+ FSSAI and FDA regulatory pathway mapping
+ Integration with 3IT Data Lake census and trade pipelines

Business Model

How the R&D engine connects to three market tracks — from compound data to commercial value.

Scroll to explore

Key Partners

  • + gBETA Accelerator
  • + Research institutions
  • + FSSAI / FDA advisors

Key Activities

  • + Computational compound screening
  • + ADMET prediction & profiling
  • + Cross-tradition convergence analysis

Key Resources

  • + 14,678 medicinal plants
  • + 908K+ compounds with structures
  • + 2.5M+ bioactivity records

Value Propositions

  • + Evidence-based formulations
  • + 12-24 month R&D reduction
  • + Regulatory-ready dossiers

Customer Relationships

  • + Research collaboration
  • + White-label partnerships
  • + Demo-driven enterprise sales

Channels

  • + 3IT.dev platform
  • + gBETA pitch events
  • + Research publications

Customer Segments

  • + Nutraceutical brands
  • + Cosmetic manufacturers
  • + Pharma R&D companies

Cost Structure

  • + Data acquisition & curation
  • + Computational infrastructure
  • + Research partnerships

Revenue Streams

  • + NutraPhyto DTC products
  • + White-label licensing
  • + R&D service contracts
  • + IP licensing

Market Tracks

Three commercialization paths — supplements, cosmetics, therapeutics — each powered by the same R&D engine.

Launching Q3 2026 $60B U.S. + $8B India supplement markets

3IT NutraPhyto

Evidence-Based Nutraceuticals

Functional food supplements formulated from computational bioactivity evidence. Compound shortlisting in days instead of months — defensible efficacy claims backed by 2.5M+ data points.

Value Proposition

  • + Science-backed formulations, not trend-chasing — every product traceable to compound data and bioactivity literature
  • + White-label clients get complete regulatory packets (CoA, evidence dossier, label claims)
  • + India-origin botanicals with strong ethnopharmacology but limited Western brand penetration

Target Segments

  • DTC science-forward consumers
  • White-label supplement brands
  • Integrative health practitioners

Revenue Streams

  • $ DTC products (60-75% gross margin)
  • $ White-label licensing ($5K-$25K + royalty)
  • $ Regulatory dossier service ($3K-$15K per claim set)
2027 $12B U.S. clean beauty + $5.5B India natural personal care

3IT PhytoCare

Bioactive Cosmetics & Personal Care

Plant-derived actives with proven antioxidant, anti-inflammatory, and UV-protective properties identified through computational screening — not marketing trends.

Value Proposition

  • + Bioactivity-selected ingredients from 2.5M+ data point screening — credible efficacy beyond "natural" labeling
  • + Full traceability from compound to crop via Lake taxonomy + GreenField farm network
  • + Novel actives from underutilized ethnobotanical species with strong bioactivity but no current cosmetic brand penetration

Target Segments

  • Clean beauty brands (ingredient supply)
  • Contract cosmetic manufacturers
  • Ayurvedic personal care companies

Revenue Streams

  • $ Bulk active ingredient supply
  • $ Formulation licensing
  • $ Efficacy testing and dossier services
2027-2028 $180B global herbal medicine + $10B India Ayurvedic pharma

3IT PhytoMed

Validated Phytopharmaceuticals

Computational validation of traditional medicine claims at scale. Reverse pharmacology decodes complex polyherbal formulas to active constituent clusters — reducing clinical trial risk and R&D timelines by 12-24 months.

Value Proposition

  • + In silico plausibility screening before expensive clinical trials — de-risks traditional medicine drug development
  • + Regulatory-ready dossiers for Ayurveda/TCM pharma clients (FDA Botanical Drug pathway, CDSCO)
  • + IP generation through novel mechanism-of-action claims on traditional formulations

Target Segments

  • Ayurvedic pharmaceutical companies
  • Botanical drug developers
  • Clinical research organizations

Revenue Streams

  • $ R&D service contracts ($50K-$500K)
  • $ IP licensing and royalties
  • $ PhytoMed Validated certification program

See the Platform in Action

30-45 minute live demo of compound screening, evidence dossier generation, and market track analysis.

Request Demo →